Clinical trials of psychedelics creates a patent gold rush
October 25, 2022
A growing number of companies are filing patent applications for natural and synthetic psychedelics encouraged by clinical trials providing evidence that their use may be helpful in treating a wide variety of mental health issues and other medical conditions. Robin Feldman, a professor at the University of California Hastings College of Law, expressed concerns about the gold rush mentality. “It’s not pretty when you look under the hood,” she said. “With psychedelics, what we’re seeing is a clash of cultures between the altruism of those who want to use existing compounds in new and exciting ways crashing up against the realities of the patent system.”
Recent News
Indeed Announces 1,000 Workers Will Be Laid Off
The job search engine is experiencing some layoffs of its own.
Walmart To Lay off Hundreds of Corporate Staff Members
Walmart is set to lay off hundreds of its corporate staff members. The retail giant will also ask their remote workers to return to the office on a hybrid schedule.
Diamond Industry Shakeup: Anglo Divorces De Beers
The diamond industry is facing a seismic shift as Anglo American Plc announces plans to part ways with its iconic De Beers business.
Home Depot’s First-Quarter Revenue Disappoints
Home Depot, a major player in the home improvement retail sector, recently released its fiscal first-quarter earnings, revealing a complex picture of consumer behavior influenced by economic factors. While the company’s earnings per share exceeded expectations, its revenue fell short, indicating a trend of deferred spending among customers.